Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole

Autor: Skedgel, C., Rayson, D., Dewar, R., Younis, T.
Zdroj: In The Breast 2007 16(3):252-261
Databáze: ScienceDirect
Externí odkaz: